Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use

Olli Kärkkäinen¹ | Marietta Kokla² | Marko Lehtonen¹ | Seppo Auriola¹ | Mika Martiskainen³,⁴ | Jari Tiihonen⁵,⁶ | Pekka J. Karhunen³ | Kati Hanhineva²,⁷ | Eloise Kok³

¹School of Pharmacy, University of Eastern Finland, Kuopio, Finland
²Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
³Faculty of Medicine and Health Technology, Tampere University and Finlab Laboratories Ltd, Tampere University Hospital Region, Kuopio, Finland
⁴Finnish Institute for Health and Welfare, Finland
⁵Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Helsinki, Finland
⁶Department of Clinical Neuroscience, Karolinska Institutet and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden
⁷Department of Biochemistry, Food chemistry and food development unit, University of Turku, Turku, Finland

Correspondence
Olli Kärkkäinen, School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland.
Email: olli.karkkainen@uef.fi

Funding Information
Finnish Foundation for Cardiovascular Research; Seventh Framework Programme, Grant/Award Number: 201668; VTR funding; Finnish Foundation for Alcohol Studies

Abstract
Heavy alcohol use is one of the top causes of disease and death in the world. The brain is a key organ affected by heavy alcohol use. Here, our aim was to measure changes caused by heavy alcohol use in the human brain metabolic profile. We analyzed human postmortem frontal cortex and cerebrospinal fluid (CSF) samples from males with a history of heavy alcohol use (n = 74) and controls (n = 74) of the Tampere Sudden Death Series cohort. We used a nontargeted liquid chromatography mass spectrometry-based metabolomics method. We observed differences between the study groups in the metabolite levels of both frontal cortex and CSF samples, for example, in amino acids and derivatives, and acylcarnitines. There were more significant alterations in the metabolites of frontal cortex than in CSF. In the frontal cortex, significant alterations were seen in the levels of neurotransmitters (e.g., decreased levels of GABA and acetylcholine), acylcarnitines (e.g., increased levels of acylcarnitine 4:0), and in some metabolites associated with alcohol metabolizing enzymes (e.g., increased levels of 2-piperidone). Some of these changes were also significant in the CSF samples (e.g., elevated 2-piperidone levels). Overall, these results show the metabolites associated with neurotransmitters, energy metabolism and alcohol metabolism, were altered in human postmortem frontal cortex and CSF samples of persons with a history of heavy alcohol use.

KEYWORDS
alcohol, alcoholism, brain, metabolomics, microbiota

1 | INTRODUCTION

Heavy alcohol use is among the top five causes of disease, disability, and death worldwide, accounting for 5% of global disease burden and nearly 10% of global deaths among populations aged 15–49 years.¹ The brain is one of the essential organs influenced by alcohol use, and many alterations in the structure and function of the brain have been associated with alcohol use.²,³
Moreover, heavy alcohol use is associated with an altered circulating metabolic profile (for a review, see Voutilainen and Kärkkäinen). For example, increased levels of glutamate, tyrosine, and phosphatidylcholine diacyls, and decreased levels of glutamine, serotonin, and phosphatidylcholine acyl-alkyls have been associated with heavy alcohol use. Furthermore, some of these changes in the circulating metabolic profile have been linked to structural changes in the white and grey matter. Moreover, in rats, it has been shown that alcohol exposure alters the brain metabolic profile. In living humans, in vivo $^1$H magnetic resonance spectroscopy can be used to measure metabolites. Although this method has shown alterations in brain metabolite levels in individuals with alcohol use disorder, for example, decreased levels of choline containing compounds, the method is limited to only measuring a handful of metabolites and does not allow for a good picture of whole metabolic profile level changes (for a review, see Meyerhoff). Similarly, there are reports on changes in many metabolite classes, for example, ethanolamines, steroids, and neurotransmitters, in human postmortem brains measured with targeted methods.

However, to our knowledge, there is no published measurement of changes in the whole human postmortem brain metabolic profile associated with heavy alcohol use to get an overall view of altered metabolic processes. Therefore, our aim here was to measure changes in the human brain metabolic profile associated with heavy alcohol use by performing a nontargeted metabolomics analysis on human postmortem frontal cortex and cerebrospinal fluid samples.

### METHODS AND MATERIALS

#### Subjects

We used samples from the Tampere Sudden Death Series (TSDS) cohort, which was collected from forensic medicine autopsies of people who suffered out of hospital death in the area of the Pirkanmaa Hospital District during 2010–2014. Frontal cortex (Broadman area 9) and CSF samples, a portion extracted via syringe, were collected from a total of 700 subjects, of which we selected 74 heavy alcohol users and 74 controls, stored at $-80^\circ$C until use. Selection of the subjects was based on autopsy reports and medical records. Inclusion criteria for the heavy alcohol use group was diagnosis of alcohol-related diseases (ICD-10 codes F10.X, G31.2, G62.1, G72.1, I42.6, K70.0-K70.4, K70.9, and K86.0) or signs of heavy alcohol use in clinical or laboratory findings (e.g., increased levels of alcohol use biomarkers gamma-glutamyl transferase, mean corpuscular volume, and carbohydrate-deficient transferrin). Lack of these findings was inclusion criteria for the control group, most of whom had died due to cardiovascular system diseases. Causes of death and general background characteristics are shown in Table 1.

#### Metabolomics analysis

Tissue samples were weighed, and 80% methanol was added (v/v H$_2$O, LC-MS Ultra CHROMASOLV®, Fluka) to a ratio of 1,000-μl

### TABLE 1  Background characteristics

|                      | Control (n = 74) | Alcohol (n = 74) | p      |
|----------------------|-----------------|-----------------|--------|
| PMI (days, mean ± SD)| 5.6 ±2.6        | 5.4 ±2.1        | 0.6432 |
| Age (years, mean ± SD)| 57 ±13          | 56 ±11          | 0.6184 |
| BMI (mean ± SD)      | 30.1 ±6.4       | 27.7 ±7.5       | 0.0377 |
| Brain (grams, mean ± SD) | 1.515 ±134    | 1.469 ±144      | 0.0490 |
| Smoking (n, %)       | 24 55%          | 27 71%          | 0.1242 |
| Liver cirrhosis (n, %)| 1 1%            | 14 19%          | 0.0046 |
| CSF alcohol (‰, mean ± SD) | 0.07 ±0.28      | 0.85 ±0.70      | <0.0001 |
| Urine alcohol (‰, mean ± SD) | 0.29 ±0.55      | 1.00 ±0.65      | 0.0045 |
| Cause of death (n, %)|                |                 |        |
| Alcohol/drug poisoning | 0 0%           | 16 22%          |        |
| Alcohol-related disease | 0 0%           | 29 39%          |        |
| Cardiovascular disease | 56 76%         | 8 11%           |        |
| Other disease        | 10 14%          | 8 11%           |        |
| Suicide              | 0 0%            | 5 7%            |        |
| Accident             | 7 9%            | 4 5%            |        |
| Unknown              | 1 1%            | 4 5%            |        |

Abbreviations: BMI, body mass index; CSF, cerebrospinal fluid; p, p value; PMI, post-mortem interval.

*Welsh’s t test.

*b$^2$ test.

*cSmoking status known only from 82 subjects (44 controls and 38 heavy alcohol users).

*dCSF alcohol concentration measured from 76 subjects (34 controls and 42 heavy alcohol users).

*eUrine alcohol concentration measured from 30 subjects (17 controls and 13 heavy alcohol users).
solvent/100-mg tissue. Extraction was facilitated by breaking the tissue with a Teflon-coated plastic stick followed by water sonication for 10 min (BRAUSON GWB 2200). For CSF samples, 100 μl of the sample was added to 400 μl of acetonitrile (VWR International, LC-MS grade) and mixed by pipette. Samples were then vortexed and centrifuged (Eppendorf centrifuge 5,804 R, 13,000 rpm, 5 min at 4°C). Supernatant was then collected and filtered into high-performance liquid chromatography (HPLC) bottles through an Acrodisc CR 4-mm (0.45 μm) filter. Quality control samples were made by taking 5 μl of solution from each sample. The samples were analyzed using an UHPLC-qTOF-MS system (Agilent Technologies, Waldbronn, Karlsruhe, Germany) that consisted of a 1,290 LC system, a Jetstream electrospray ionization (ESI) source, and a 6,540 UHD accurate-mass qTOF spectrometer. Details of the method have been previously published.15 In brief, two different chromatographic techniques were used, that is, reversed phase (RP, Zorbax Eclipse XDB-C18, particle size 1.8 μm, dimensions of 2.1 x 100 mm, Agilent Technologies, USA) and hydrophilic interaction (HILIC, Acquity UPLC BEH Amide 1.7 μm, 2.1 x 100 mm, Waters, Ireland) chromatography and data acquired at both positive (+) and negative (−) polarity. RP chromatography: column oven temperature was set to 50°C, and the flow rate to 0.4 ml/min gradient elution with water (eluient A) and methanol (eluient B) both containing 0.1% (v/v) of formic acid. Gradient profile for RP separations was: 0–10 min: 2% B → 100% B; 10–14.5 min: 100% B; 14.5–14.51 min: 100% B → 2% B; 14.51–16.5 min: 2% B. HILIC: column oven temperature was set to 45°C, flow rate 0.6 ml/min, gradient elution with 50% v/v ACN in water (eluient A) and 90% v/v ACN in water (eluient B), both containing 20-mM ammonium formate (pH 3). The gradient profile for HILIC separations was: 0–2.5 min: 100% B, 2.5–10 min: 100% B → 0% B; 10–10.01 min: 0% B → 100% B; 10.01–12.5 min: 100% B. The sample tray was kept at 4°C during analysis. MassHunter Acquisition B.07.00 (Agilent Technologies) software was used for data acquisition. The quality control samples were injected at the beginning of the analysis as well as every 12th injection. The analysis order of the samples was randomized. We used three different collision-induced dissociation voltages (10, 20, and 40 eV) for the data-dependent tandem mass spectrometry (MSMS) analysis. The mass spectrometry data processing was performed using MS-DIAL ver. 3.40.16 The peak picking and peak alignment parameters were as follows: mass range from 40 to 1,000 (HILIC) or 1,600 (RP) Da, MS tolerance 0.005 Da, MS2 tolerance 0.01 Da, minimum peak width 10 scans, minimum peak height 10,000 (selected based on background noise level). Peaks needed to be detected in at least 70% of samples from one study group to be included in the final data matrix. Drift correction of the metabolomics data was done using results from the QC sample, according to a previously published protocol.15 In brief, the molecular features were corrected for the drift pattern caused by the LC–MS procedures using regularized cubic spline regression, fit separately for each feature on the QC samples. The smoothing parameter was chosen from an interval between 0.5 and 1.5 using leave-one-out cross validation to prevent overfitting. After the drift correction, feature quality was assessed, and low-quality features were flagged. Features were kept if their RSD* was below 20% and their D-ratio below 40%. In addition, features with classic RSD, RSD* and basic D-ratio all below 10% were kept. This additional condition prevents the flagging of features with very low values in all but a few samples. Missing values were imputed using random forest imputation. QC samples were removed prior to imputation to prevent them from affecting imputation.

Metabolite identification was focused on statistically significantly altered molecular features. Metabolite identification was based on exact mass, MSMS fragmentation, and retention time. Identifications were ranked according to common guidelines.17 Metabolites in Level 1 were matched to the mass, retention time, and MS/MS spectra of fragmented ions from the in-house library built of chemical standards using the same instrument and experimental conditions. Level 2 includes metabolites matching the exact mass and MSMS spectra from public libraries (METLIN, Lipidmaps, and Human Metabolome DataBase were used) or in the case of lipids, the built-in MS-DIAL library version 3.40. In Level 3, only the chemical group of the compound (but not the exact compound) is identifiable. Level 4 indicates unidentified compounds.

2.3 | Statistical analysis

We used Welch’s t test (continuous variables) and $\chi^2$ test (binominal variables) to evaluate differences between the study groups in background characteristics. We used Welch’s t test and Cohen’s d effect sizes to evaluate differences between the study groups in the metabolomics data. To account for multiple testing, we adjusted the $\alpha$ level by the number of principal components needed to explain 95% of the variation in the data. For correlations, we used Spearman’s correlations. We used JASP (JASP team 2019, version 0.10) for statistical analyses.

3 | Results

Based on background information, the heavy alcohol user group had lower brain weight and lower body mass index (BMI) when compared with controls (Table 1). Moreover, as expected, the heavy alcohol use group had more cases of liver cirrhosis, as well as higher CSF and urine alcohol concentrations at time of death. It should be noted that smoking information was available for only 85 subjects (57%). When evaluated from the point of metabolomics data, there was no significant difference between study groups in the level of cotinine (a metabolite of nicotine, p values in frontal cortex and CSF were 0.1370 and 0.1251, respectively).

In the principal component analysis, 96 latent variables were needed to explain 95% of variance in the metabolomics data. Therefore, to account for multiple testing, we reduced the $\alpha$ level to 0.0005. Molecular features with $p$ values between 0.0005 and 0.05 were considered to be trends. There were more significantly altered molecular features in the frontal cortex samples between the study groups than in the CSF samples. We detected 2,471 molecular features in the frontal cortex samples, of which 939 had $p$ values below
Volcano plots of metabolic profile changes in the frontal cortex and cerebrospinal fluid samples. Ninety-six latent variables were the metabolite levels and PMI, age, and BMI, after correction for altered metabolites, there were no significant correlations between which are shown in Tables S1 and S2. Of the statistically significantly levels and postmortem interval (PMI), age at time of death and BMI, 

| Metabolite                     | Frontal Cortex | CSF          |
|--------------------------------|----------------|--------------|
| 2-Piperidone                   | Increased     | Increased    |
| 3-Hydroxyisovaleric acid       | Decreased     | Decreased    |
| GABA                           | Decreased     | Decreased    |
| Acetylcholine (ACh)            | Decreased     | Decreased    |

Identified metabolites that had a value < 0.05 when comparing study groups are shown in Tables S1 (frontal cortex) and S2 (CSF). Overall, we were able to identify more altered metabolites from the frontal cortex samples than from the CSF samples. Of note is that the MSMS spectrum of 2-piperidone was similar to 5-aminovaleate [M-OH+], but the retention time was different (RP positive mode retention time for 2-piperidone was 2.1 min, and 4.3 min for 5-aminovaleate). All measured molecular features are shown in Table S4.

In the frontal cortex samples, after correction for multiple testing, we observed significantly increased levels of 2-piperidone (d = 1.03), carnosine (d = 0.74), acetylcarnitine 20:1 (d = 0.72), 3-hydroxyisovaleric acid (d = 0.71), and acetylcarnitine 4:0 (d = 0.68), and significantly decreased levels of GABA (d = −0.81), acetylcholine (d = −0.71), cystine (d = −0.63), glutaryl carnitine (d = −0.60), aspartic acid (d = −0.59), and 25-hydroxycholesterol (d = −0.59, Figure 2). Furthermore, in the CSF samples, after correction for multiple testing, we observed significantly increased levels of 2-piperidone (d = 1.04, similar to frontal cortex), aspartyl-proline (Asp-Pro, d = 0.95), ethyl hydrogen sulfate (found in beer, d = 0.88), 3-hydroxyisovaleric acid (d = 0.76, similar to frontal cortex), and leucic acid (d = 0.65, Figure 2).

There were some correlations between the measured metabolite levels and postmortem interval (PMI), age at time of death and BMI, which are shown in Tables S1 and S2. Of the statistically significantly altered metabolites, there were no significant correlations between the metabolite levels and PMI, age, and BMI, after correction for multiple testing, with the exception of acetylcholine and BMI (r = 0.30, p = 0.00019), 25-hydroxycholesterol and age at the time of death (r = −0.37, p < 0.00001).

Correlations between frontal cortex and CSF levels of metabolites, which had p values below 0.05 in both measured sample types, are shown in Table S3. There were significant correlations between frontal cortex and CSF samples in many of the altered metabolites, including 2-piperidone and 3-hydroxyisovaleric acid.

4 | DISCUSSION

In the present study, we found differences in the metabolic profile of human postmortem brain and CSF samples associated with a history of heavy alcohol use compared with controls. This is in line with previous studies showing that heavy alcohol use is associated with an altered metabolic profile in blood, urine, and other organs (for a review, see Voutilainen and Kärkkäinen). We observed decreased levels of GABA in the frontal cortex samples of heavy alcohol users. Results from previous studies using human brain in vivo 1H magnetic resonance spectroscopy in persons with alcohol use disorder have produced mixed results, with some studies showing low GABA levels, whereas other studies have reported no significant changes in GABA levels. These differences could be related to populations and timing of the analysis (e.g., subjects’ intoxication status, whether subjects are in withdrawal of abstinence and for how long). Previous postmortem brain studies have reported decreased levels of GABA-A receptors and GABA transporters in persons with alcohol dependence. Overall, the present results support the view that the GABAergic system is altered...
in persons with a history of heavy alcohol use associated with, for example, development of dependence and increased risk of seizures during withdrawal.

Furthermore, we observed increased levels of 2-piperidone (δ-valerolactam) in the frontal cortex and CSF samples of heavy alcohol users. 2-Piperidone is a metabolite of cadaverine via intermediate 1-piperideine, which can also be metabolized to a GABA analog 5-aminovalerate. 23 2-Piperidone is a substrate for cytochrome P450-2E1 (CYP2E1), which metabolizes 2-piperidone to 6-hydroxy-2-piperidone. 24 2-Piperidone has been suggested to be a biomarker of CYP2E1 activity. 24 Therefore, high 2-piperidone levels observed in the present study could be associated with alcohol-induced inhibition of 2-piperidone metabolism by blocking its access to the CYP2E1 enzyme. CYP2E1 has an important role in alcohol-induced changes in the function of the brain because it produces acetaldehyde, which has been associated with the behavioral effects of alcohol. 25 Further research is needed to understand the possible biological role of 2-piperidone in the brain and investigate if 2-piperidone levels are also increased in the plasma or urine in heavy alcohol users.

Moreover, the cholinergic system of the brain is considered to be important in the development of alcohol dependence. 26 We observed significantly decreased levels of acetylcholine and a trend in decreased choline levels in the frontal cortex samples, which is in line with a previous in vivo 1H magnetic resonance spectroscopy study where decreased levels of choline containing molecules were measured in persons with alcohol use disorder. 20 In contrast, these postmortem brain results show a trend towards increased levels of many lysophosphatidylcholines (lysoPCs) and phosphocholine (Table S1). This indicates that the choline balance has shifted towards lysoPCs, compared with free choline or acetylcholine. LysoPCs can increase NFkB activation 27 and the recruitment of microglia, 28 and increased levels have been reported in animal models of brain damage 29 and in human postmortem samples from persons with Alzheimer’s disease. 30

**FIGURE 2** Significantly altered metabolites. Heavy alcohol use was associated with significant (corrected α level = 0.0005 to account for multiple testing) differences in metabolite levels in both postmortem frontal cortex and cerebrospinal fluid (CSF) samples when compared with controls. High 2-piperidone and 3-hydroxyisovaleric acid levels were observed in the heavy alcohol use group in both frontal cortex and CSF samples. Mean ion abundance and 95% confidence intervals are shown. Legend: d, Cohen’s d effect size; GABA, gamma-aminobutyric acid; p, p value from Welch’s t test.
Furthermore, in the present study, we observed significantly decreased levels of aspartic acid and trends toward decreased levels of both N-acetylaspartate (NAA) and N-acetylaspartylglutamic acid (NAAG) in postmortem frontal cortex brain samples (Table S1). This is in line with previous studies showing decreased NAA peaks (consisting of both NAA and NAAG in magnetic resonance spectroscopy) in frontal cortex and white matter in association with heavy alcohol use. Decreased aspartic acid levels could be associated with alcohol caused ketosis, and NAA and NAAG levels are considered to be a sign of decreased neuronal viability and/or integrity. However, NAA is also found in myelin, and low NAA levels have been associated with myelin damage. Therefore, the present results of decreased aspartic acid, NAA, and NAAG levels could be a sign of gray and white matter damage in the frontal cortex in the heavy alcohol users. Many changes were seen in lipid metabolism in the frontal cortex and CSF samples especially in levels of acylcarnitines (AC), phosphatidylcholines (PC), lysophosphatidylcholines (PE), and lysophosphatidylethanolamines (lysoPCs) and lysophosphatidylethanolamines (lysoPEs) (Tables S1 and S2). Altered circulating lipid levels have previously been reported in persons with alcohol use disorder. Altered lipid metabolism in the frontal cortex could be linked to altered energy metabolism in general in these samples, as seen also in other markers of altered energy metabolism like NAA and NAAG. Moreover, altered phospholipid levels could be associated with commonly reported alterations in the brain structure seen in persons with a history of heavy alcohol use, indicated here as reduced brain weight, because phospholipids are major components of cell membranes.

High 3-hydroxyisovaleric acid levels observed in both frontal cortex and CSF samples in the heavy alcohol use group could be associated with a combination of biotin deficiency and smoking. 3-Hydroxyisovaleric acid is a byproduct of the leucine degradation pathway made by the biotin-dependent enzyme 3-methylcrotonyl-Co A carboxylase. The main limitation of the present study is that PMI could influence the results because many metabolic processes continue after death. However, after correcting for multiple testing, all metabolites with significant differences between the study groups did not significantly correlate with PMI. This indicates that PMI is likely not causing the differences between the study groups of significantly altered metabolites. Other possible confounding factors include that differences in medical diagnoses (there are no healthy controls in postmortem studied) and used medications have been different between the cases and controls. For example, the metabolomics analysis showed that the controls used more metoprolol and the cases more nordiazepam, which could affect the seen results, for example, the decreased GABA levels (Table S1). Moreover, future studies should also analyze samples from females and different brain regions, because alcohol use could influence the metabolic profile differently in different genders and brain regions.

In conclusion, we show here that postmortem frontal cortex and CSF samples from persons with a history of heavy alcohol use have an altered metabolic profile when compared with samples from control subjects. Most alterations could be associated with neurotransmitter and energy metabolism, but metabolites associated with gut microbiota were also altered. Further studies are needed in other brain regions and with preclinical models to understand the spatial and temporal aspects of how heavy alcohol use alters the brain metabolic profile with connection to alcohol-related diseases.

ACKNOWLEDGMENTS
We thank Milla Reponen for the excellent technical assistance with the mass spectrometry analyses. This study is funded by the Finnish Foundation for Alcohol Studies (OK), VTR funding (JT and PJK), European Union 7th Framework Program Grant 2016-68 for AtheroRemo Project (PJK), and the Finnish Foundation for Cardiovascular Research (PJK). The authors want to thank Biocenter Finland and Biocenter Kuopio for supporting their core LC–MS laboratory facility.

AUTHOR CONTRIBUTIONS
OK and EK were responsible for the metabolomics study concept and design. PJK, MM, and EK designed the collection of the TSDS cohort. ML and SA supervised the mass spectrometry analysis. MK did preprocessing of the metabolomics data. OK did statistical analysis and interpretation of the findings and drafted the manuscript. JT, PJK, KH, and EK provided critical revision of the manuscript for important intellectual content. All authors critically reviewed content and approved the final version for publication.

CONFLICT OF INTEREST
OK and KH are founders of Afekta Technologies Ltd., a company offering metabolomics analysis services. Other authors report no potential conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Olli Kärkkäinen https://orcid.org/0000-0003-0825-4956

REFERENCES
1. Griswold MG, Fullman N, Hawley C, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2018;392(10152):1015-1035.
2. de la Monte SM, Kril JJ. Human alcohol-related neuropathology. Acta Neuropathol (Berl). 2014;127:71-90.
3. Abrahao KP, Salinas AG, Lovinger DM. Alcohol and the brain: neuronal molecular targets, synapses, and circuits. Neuron. 2017;96(6):1223-1238.
4. Voutilainen T, Kärkkäinen O. Changes in the human metabolome associated with alcohol use: a review. Alcohol Alcohol. 2019;54(3):225-234.
5. Jaremk M, Yu Z, Mangino M, et al. Alcohol-induced metabolomic differences in humans. Transl Psychiatry. 2013;3(7):e276-e276.
6. Würz P, Cook S, Wang Q, et al. Metabolic profiling of alcohol consumption in 9778 young adults. Int J Epidemiol. 2016;45(5):1493-1506.
7. Lehikoinen AI, Kärkkäinen OK, Lehtonen MAS, Aurola SOK, Hanhineva KJ, Heinonen ST. Alcohol and substance use are associated with altered metabolome in the first trimester serum samples of pregnant mothers. Eur J Obstet Gynecol Reprod Biol. 2018;223:79-84.

8. Heikkinen N, Kärkkäinen O, Laukkanen E, et al. Changes in the serum metabolite profile correlate with decreased brain gray matter volume in moderate-to-heavy drinking young adults. Alcohol. 2019; 75:89-97.

9. Shen Q, Heikkinen N, Kärkkäinen O, et al. Effects of long-term adolescent alcohol consumption on white matter integrity and their correlations with metabolic alterations. Psychiatry Res Neuroimaging. 2019;294:111003.

10. Meinhardt MW, Sévin DC, Klee ML, Dieter S, Sauer U, Sommer WH. The neurometabolite fingerprint of excessive alcohol drinking. Neuropsychopharmacology. 2015;40(5):1259-1268.

11. Meyerhoff DJ. Brain proton magnetic resonance spectroscopy of alcohol use disorders. In: Handbook of Clinical Neurology. Vol.125. Elsevier; 2014:313-337.

12. Kashem MA, Ahmed S, Sultana N, et al. Metabolomics of neurotransmitters and related metabolites in post-mortem tissue from the dorsal and ventral striatum of alcoholic human brain. Neurochem Res. 2016; 41(1-2):385-397.

13. Kärkkäinen OK, Lehtonen M, Laukkanen V, et al. Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics. Alcohol. 2013;47(5):399-403.

14. Kärkkäinen O, Häkkinen MR, Aurola S, Kautiainen H, Tiihonen J, Stovrik M. Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics. Alcohol. 2016;52:63-70.

15. Klavins K, Koal T, Dallmann G, Marksteiner J, Kemmler G, Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:295-302.

16. Tsugawa H, Cajka T, Kind T, et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Metabolomics. 2015;3(3):211-221.

17. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis: chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics. 2007; 3(3):211-221.

18. Behar KL, Rothman DL, Petersen KF, et al. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry. 1999;156(4):952-954.

19. Mason GF, Petrakis IL, de Graaf RA, et al. Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. Biol Psychiatry. 2004;59(1):85-93.

20. Mon A, Durazzo TC, Meyerhoff DJ. Glutamate, GABA, and other cortical metabolite concentrations during early abstinence from alcohol and their associations with neurocognitive changes. Drug Alcohol Depend. 2012;125(1-2):27-36.

21. Laukkanen V, Stovrik M, Häkkinen M, et al. Decreased GABAA benzodiazepine binding site densities in postmortem brains of Cloninger type 1 and 2 alcoholics. Alcohol. 2013;47(2):103-108.

22. Augier E, Barbier E, Dulman RS, et al. A molecular mechanism for choosing alcohol over an alternative reward. Science. 2018; 360(6395):1321-1326.

23. Scalley PS, Geelhaar LA. Biosynthesis of 5-aminopentanoic acid and 2-piperidine from cadaverine and 1-piperidine in mouse. J Neurochem. 1984;49(6):1631-1634.

24. Cheng J, Chen C, Kristopher KW, et al. Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping. Toxicol Sci J Soc Toxicol. 2013;135(1):37-47.

25. Heit C, Dong H, Chen Y, Thompson DC, Deitrich RA, Vasiliou VK. The role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system. Subcell Biochem. 2013;67:235-247.

26. Wu J, Gao M, Taylor DH. Neuronal nicotinic acetylcholine receptors are important targets for alcohol reward and dependence. Acta Pharmacol Sin. 2014;35(3):311-315.

27. Masamune A, Sakai Y, Yoshida M, Satoh A, Satoh K, Shimosegawa T. Lysophosphatidylcholine activates transcription factor NF-κB and AP-1 in AR42J cells. Dig Dis Sci. 2001;46(9):1871-1881.

28. Inose Y, Kato Y, Kitagawa K, Uchiyama S, Shibata N. Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes: LPC activates microglia in penumbra. Neuropathology. 2015;35(3):209-223.

29. Topozi S, Kolosowska N, Kärkkäinen O, et al. HSX600, a synthetic agonist for RXR-Nur1 heterodimer complex, prevents ischemia-induced neuronal damage. Brain Behav Immun. 2018;73:670-681.

30. Klavins K, Koal T, Dallmann G, Marksteiner J, Kemmler G, Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. Alzheimers Dement Diagn Assess Dis Monit. 2015;1:295-302.

31. Jagnanathan NR, Desai NG, Raghunathan P. Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study. Magn Reson Imaging. 1996;14(5):553-557.

32. Seitz D, Widmann U, Seeger U, et al. Localized proton magnetic resonance spectroscopy of the cerebellum in detoxifying alcoholics. Alcohol Clin Exp Res. 1999;23(1):158-163.

33. Bendszus M, Weijers H-G, Wiesbeck G, et al. Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data. Am J Neuroradiol. 2001;22(10):1926-1932.

34. Parks MH, Dawant BM, Riddle WR, et al. Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. Alcohol Clin Exp Res. 2002;26(9):1368-1380.

35. Durazzo TC, Gazdzinski S, Barns P, Meyerhoff DJ. Cigarette smoking exacerbates chronic alcohol-induced brain damage: a preliminary metabolite imaging study. Alcohol Clin Exp Res. 2004;28(12):1849-1860.

36. Ende G, Welzel H, Walter S, et al. Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study. Biol Psychiatry. 2005;58(12):974-980.

37. Wang J, Durazzo TC, Gazdzinski S, Yeh P-H, Mon A, Meyerhoff DJ. MRSI and DTI: a multimodal approach for improved detection of white matter abnormalities in alcohol and nicotine dependence. NMR Biomed. 2009;22(5):516-522.

38. Yudkoff M, Daikhy N, Nissim I, et al. Response of brain amino acid metabolism to ketosis. Neurochem Int. 2005;47(2-1):119-128.

39. Baslow MH. N-Acetylasparglute in the vertebrate brain: metabolism and function. Neurochem Res. 2003;28(6):941-953.

40. Baslow M, Guilfoyle D. Using proton magnetic resonance imaging and spectroscopy to understand brain “activation”. Brain Lang. 2007;102(2):153-164.

41. Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. Am J Neuroradiol. 2007;28(10):1843-1849.

42. Nordengen K, Heuser C, Rinholm JE, Matalon R, Gundersen V. Localisation of N-acetylaspartate in oligodendrocytes/myelin. Brain Struct Funct. 2003;28(6):941-953.

43. Lacruz ME, Kluttig A, Tiller D, et al. Cardiovascular risk factors associated with blood metabolite concentrations and their alterations during a 4-year period in a population-based cohort. Circ Cardiovasc Genet. 2016;9(6):487-494.

44. van Roekel E, Trijsburg L, Assi N, et al. Circulating metabolites associated with alcohol intake in the European prospective investigation into cancer and nutrition cohort. Nutrients. 2018;10(5):654.
45. Sealey WM, Teague AM, Stratton SL, Mock DM. Smoking accelerates biotin catabolism in women. *Am J Clin Nutr.* 2004;80(4):932-935.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Kärkkäinen O, Kokla M, Lehtonen M, et al. Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use. *Addiction Biology*, 2021; e13035. [https://doi.org/10.1111/adb.13035](https://doi.org/10.1111/adb.13035)